Fluorofuranylnorprogesterone F-18

DB15282InvestigationalSmall molecule

Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).

Mechanism: Pharmacologically active on Progesterone receptor
Curator reviewed
Formula / weight: C₂₅H₂₉FO₅ · 427.503 g/mol (avg)
Also known as: 19-NORPREGN-4-ENE-3,20-DIONE, 21-(FLUORO-18F)-16,17-((R)-(2-FURANYLMETHYLENE)BIS(OXY))-, (16.ALPHA.)- · F18-FFNP · Fluorofuranylnorprogesterone (18F)

Resolves to

Compound

UNII3I798OGQ8BCAS160388-43-2ChEMBLCHEMBL4297379

Structure

InChIKeyVJKRBRUNEOHPBS-JQKUZGBFSA-NSMILESC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C[C@H]1O[C@H](O[C@@]21C(=O)C[18F])C1=CC=CO1

Targets

P06401PGR

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fluorofuranylnorprogesterone F-18, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account